Quintiles Exec Makes Case to Congress for Reducing Clinical Trial Timelines
Cohen addresses the three-pronged parts of drug development process or clinical trials
Quintiles released the written remarks, its Senior Vice President and Global Head of Early Clinical Development, Oren Cohen, MD, will make today October 9, to a Congressional Roundtable being held in Research Triangle Park, NC. The roundtable is an outgrowth of the U.S. House Energy & Commerce Committee’s 21st Century Cures Initiative and will focus on the discovery, development, and delivery of vaccines.
In these remarks, again specific to vaccines, Cohen addresses the three-pronged parts of drug development process or clinical trials; pathways or regulatory alternatives to minimize clinical development times, and preparedness for development of vaccines.
Under clinical trials or process, interestingly, Cohen targets ECs and IRB inefficiencies, promotes eSource Data Capture and the enforced use of common data standards, such as those created by CDISC.
Under pathways, Cohen believes an adaptive licensing approach similar to the EMA pilots now underway, would be helpful for FDA in regard to vaccine development.
Dr. Cohen is an infectious diseases expert and head’s Quintiles’ Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (US) and London.
Read the full release here.
The following infographic was sent with the press release. (Click to enlarge).
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
